Stealth BioTherapeutics (MITO) Reports In-Line Q3 EPS

Stealth BioTherapeutics (NASDAQ: MITO) reported Q3 EPS of ($0.02), in-line with the analyst estimate of ($0.02).

"As we move into the fourth quarter, we are proud that our team has stayed focused, execution-oriented, excited about our platform potential, and dedicated to the patients we serve during what has been a challenging year," said Reenie McCarthy, chief executive officer of Stealth. "We have learned important lessons that both inform our future development of elamipretide for diseases of mitochondrial dysfunction and stoke our enthusiasm in our deep pipeline of mitochondrial therapeutics. We are thrilled that with Morningside's continued financial support under our recently announced development funding agreement, we are well-positioned to progress our first-in-class development efforts in 2021."

For earnings history and earnings-related data on Stealth BioTherapeutics (MITO) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c
• Lucid Diagnostics Inc. (LUCD) Reports In-Line Q2 EPS